MRVI vs CPRX
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 01, 2026
MRVI
55.0
AI Score
VS
CPRX Wins
CPRX
58.5
AI Score
Investment Advisor Scores
CPRX
59score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MRVI | CPRX | Winner |
|---|---|---|---|
| Revenue | 65.84M | 149.39M | CPRX |
| Net Income | -3.73M | 63.73M | CPRX |
| Net Margin | -5.7% | 42.7% | CPRX |
| Operating Income | -2.16M | 73.23M | CPRX |
| ROE | -1.8% | 6.3% | CPRX |
| ROA | -0.5% | 5.6% | CPRX |
| Total Assets | 713.22M | 1.15B | CPRX |
| Cash | 165.92M | 755.86M | CPRX |
| Current Ratio | 5.91 | 7.10 | CPRX |
| Free Cash Flow | 4.23M | 59.56M | CPRX |
Relative Price Performance (Last 90 Days)
MRVI 1M: +6.8%
· 3M: +78.5%
CPRX 1M: +0.4%
· 3M: +24.3%
Current Technical Phase
MRVI
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (22.4% over 20 days), RSI 54
CPRX
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (6.9% over 20 days), RSI 71
Fundamentals Snapshot
| Metric | MRVI | CPRX |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -71.7 | 9.9 |
| Trailing P/E | — | 18.2 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.4% | 0.1% |
| Gross Margin | 0.3% | 0.8% |
| Operating Margin | 0.0% | 0.5% |
| EPS | -0.68 | 1.73 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, CPRX is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.